Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset
Status:
Completed
Trial end date:
2019-10-30
Target enrollment:
Participant gender:
Summary
Stroke is one of the leading causes of death and disability in China. Intravenous
thrombolysis with recombinant tissue plasminogen activator (rtPA) improves the outcome for
ischemic stroke patients who can be treated within 4.5 hours of symptom onset. In China, in
addition to rt-PA, intravenous urokinase within 6 h has also been recommended by the 2010
Chinese Guidelines for the Diagnosis and Treatment of Patients with Acute Ischemic Stroke,
and supported by evidence from two intravenous urokinase thrombolysis trials. Urokinase is
used more frequently than rt-PA, mainly because it is cheaper. To describe Chinese experience
with thrombolytic therapy for Ischemic Stroke within 4.5h onset, we designed a multicenter,
prospective, registry study. The aim of INtravenous Thrombolysis REgistry for Chinese
Ischemic Stroke within 4.5 h onset（INTRECIS）was to assess the safety and efficacy of
intravenous rtPA, urokinase as thrombolytic therapy within the first 4.5 h of onset of acute
ischaemic stroke.